Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $0.50 per share which missed the analyst consensus estimate of $0.53 by 5.66 percent. This is a 308.33 percent increase over losses of $(0.24) per share from the same period last year. The company reported quarterly sales of $121.70 million which beat the analyst consensus estimate of $120.16 million by 1.28 percent. This is a 126.78 percent increase over sales of $53.66 million the same period last year.